Press Release

Ferring Presents $1,000 to Honorable Mention Winner

Mike Seckler, eastern district manager, Ferring Pharmaceuticals, presents Joann Holmes, honorable mention winner of Ferring’s My Little Miracle Essay Contest, with a $1,000 prize to be deposited in an education fund for her son, Grayson Zinck-Holmes. Grayson was born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Christina R. Veit, M.D.; Mary, Joann’s partner, Joann Holmes holding Grayson; Mike Seckler, Ferring Pharmaceuticals.

Tarrytown, NY – November 30, 2004 – Christina R. Veit, M.D., announced today that her patient, Joann Holmes, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Joann’s entry, My Little Miracle, chronicled the path to her son’s birth. The prize money will be deposited into an education fund for Grayson G. Zink-Holmes, her eight-month-old son born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 29th at Dr. Veit’s office in Tarrytown.

“Ferring Pharmaceuticals helped to provide us with a wonderful future through the birth of our son,”said Joann Holmes. “Through this award, Ferring is now helping to provide for his future. We couldn’t be more grateful!”

“Our office was really excited to meet Joann’s new baby,”added Christina R. Veit, M.D. “Ferring’s generous program has helped Joann start to plan for Grayson’s education and we are happy to have been a part of bringing Joann and Ferring together.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,”added Mike Seckler, eastern district manager, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About Joann Holmes

Joann Holmes and her partner, Mary, decided to seek fertility treatment in the Spring of 2003. Since Joann was over 40-years-old at the time they decided to seek treatment, she was concerned about her chances of successfully conceiving a child. They decided that Joann would carry their first child and Mary would carry their second. In her essay, written as a poem, Joann, speaks of their experience:

On the first of March two thousand and four, My little miracle arrived with a roar. With the sound of his voice and the look of his face, Came a small piece of heaven right here in this place. With his eyes big and blue and a heart pure as gold, Our baby, our joy, is a wonder to hold. But let us go back and provide an account, Of our journey through fear, self pity and doubt. We started our family late in the game, And were told that our chances were really quite lame. Saddened and troubled we reached out for hope, And thought that this might be the end of our rope. Our research on how to proceed was a chore,

A drug that could help us – could this be our cure? With hope on the rise and our prayers for the best, We started injections of Ferring’s Repronex™. A few months had passed and one day we heard, It really has happened – we then spread the word. This wonderful news we could hardly believe, A drug called Repronex™ had helped us conceive! When he arrived, our sweet little boy, Our hearts were filled with love and laughter and joy. Our blessings are counted over again, And we share in a love that will never end. Our story is one of thousands you see, Of all who’ve been helped to have a baby. This treatment is true and not just empirical, The proof is in seeing my little miracle!

Joann and Mary are expecting their second child in late May 2005.

About Bravelle™ and Repronex™

Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression.Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

About Christina R. Veit, M.D.
Christina R. Veit, M.D., is a board certified obstetrician gynecologist. Dr. Veit specializes in gynecology, reproductive endocrinology, fertility, polycystic ovarian syndrome (PCOS) and menopause. Services provided in Dr. Veit’s private practice include family planning; evaluation and treatment of PCOS, endometriosis, fibroids and couples with fertility concerns; laparoscopy; hysteroscopy; intrauterine insemination (IUI); and in vitro fertilization (IVF). The practice support staff consists of a registered nurse, a medical assistant, a board-certified sonographer and administrative personnel. For more information, visit www.veitmd.com or call (914) 631-1292.

# #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.